101 related articles for article (PubMed ID: 38721643)
1. Global burden and economic impact of vaccine-preventable cancer mortality.
Bencina G; Oliver E; Meiwald A; Hughes R; Morais E; Weston G; Sundström K
J Med Econ; 2024 Apr; 27(sup2):9-19. PubMed ID: 38721643
[TBL] [Abstract][Full Text] [Related]
2. The indirect costs of human papillomavirus-related cancer in Central and Eastern Europe: years of life lost and productivity costs.
Sabale U; Karamousouli E; Popovic L; Krasznai ZT; Harrop D; Meiwald A; Hughes R; Weston G; Bencina G
J Med Econ; 2024 Apr; 27(sup2):1-8. PubMed ID: 38638098
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
6. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
8. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
9. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis.
Bonjour M; Charvat H; Franco EL; Piñeros M; Clifford GM; Bray F; Baussano I
Lancet Public Health; 2021 Jul; 6(7):e510-e521. PubMed ID: 33864738
[TBL] [Abstract][Full Text] [Related]
10. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020-30: a modelling study.
Hartner AM; Li X; Echeverria-Londono S; Roth J; Abbas K; Auzenbergs M; de Villiers MJ; Ferrari MJ; Fraser K; Fu H; Hallett T; Hinsley W; Jit M; Karachaliou A; Moore SM; Nayagam S; Papadopoulos T; Perkins TA; Portnoy A; Minh QT; Vynnycky E; Winter AK; Burrows H; Chen C; Clapham HE; Deshpande A; Hauryski S; Huber J; Jean K; Kim C; Kim JH; Koh J; Lopman BA; Pitzer VE; Tam Y; Lambach P; Sim SY; Woodruff K; Ferguson NM; Trotter CL; Gaythorpe KAM
Lancet Glob Health; 2024 Apr; 12(4):e563-e571. PubMed ID: 38485425
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
12. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
13. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
[TBL] [Abstract][Full Text] [Related]
14. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
16. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
18. Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003.
Ekwueme DU; Chesson HW; Zhang KB; Balamurugan A
Cancer; 2008 Nov; 113(10 Suppl):2936-45. PubMed ID: 18980277
[TBL] [Abstract][Full Text] [Related]
19. The global burden of vaccine-preventable infectious diseases in children less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?
Frenkel LD
Allergy Asthma Proc; 2021 Sep; 42(5):378-385. PubMed ID: 34474707
[No Abstract] [Full Text] [Related]
20. Breast cancer-related mortality in Central and Eastern Europe: years of life lost and productivity costs.
Bencina G; Chami N; Hughes R; Weston G; Baxter C; Maciejczyk A; Popovic L; Karamousouli E; Salomonsson S
J Med Econ; 2023; 26(1):254-261. PubMed ID: 36756852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
